Pharmacological treatment of inflammation using anxA1 and its N-terminal peptide has been studied in mouse models of neutrophil-dependent edema [20], cardiac ischemia-reperfusion injury [21,22] and acute peritonitis [23], however, hitherto not in atherosclerosis. Here, ANXA1 is linked to atherosclerosis.